Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2

Conditions

Pancreatic Neoplasms 1Neuroendocrine Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoid Tumor 1Adenoma, Islet Cell 1

Interventions

Oxaliplatin 154Fluorouracil 138Gemcitabine 119Bevacizumab 115Leucovorin 106Specimen Handling 105Capecitabine 96pembrolizumab 90Magnetic Resonance Spectroscopy 82Nivolumab 80Cisplatin 80Irinotecan 72durvalumab 63Cetuximab 62Paclitaxel 60Biopsy 60130-nm albumin-bound paclitaxel 58Radiotherapy 49atezolizumab 44Albumin-Bound Paclitaxel 38Taxes 36Carboplatin 36Folfox protocol 34Drug Therapy 33lenvatinib 29dehydroftorafur 29sintilimab 28Cyclophosphamide 28tislelizumab 27Radiation 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
lanreotide × Gastrointestinal × 90 days × Clear all
NCT06807437 2026-03-31

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

SWOG Cancer Research Network

Phase 3 Recruiting
274 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡